News & Analysis as of

Emerging Growth Companies Life Sciences

Emerging Growth Companies (EGC) are companies with total yearly gross revenues of under $1 billion for the most recently completed fiscal year.  
Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 3 - International Clinical Trials Country Requirements-...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 2 - AI In Real Life (Science): Exploring Real World...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 1 - Navigating Risk from Lab to IPO: A Guide to...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Fenwick & West LLP

Key Takeaways: Navigating the Life Sciences IPO Journey

Fenwick & West LLP on

The journey to becoming a public company requires strategic planning and thoughtful coordination. While the IPO process typically spans six months or more, laying the groundwork should begin much earlier to ensure a smooth...more

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 204: Accelerating Life Sciences Startups with James...

Maynard Nexsen on

This week, hosts Matthew and Heather welcome back James Chappell, President and CEO of SCbio, to discuss the organization’s new program, SCbioDrive, an accelerator program for emerging life sciences companies. The group...more

DLA Piper

FemTech and the use of AI

DLA Piper on

Due to an exponential growth in the investment in female health and wellbeing, Forbes and Dealroom reported that 2023 saw 1.14 billion USD raised collectively across 120 deals in ‘FemTech’. ...more

Wilson Sonsini Goodrich & Rosati

2023 Technology and Life Sciences IPO Report

Market volatility, high interest rates, and ongoing geopolitical conflict continue to influence low levels of IPO activity in the U.S. capital markets. The trend is observed across all sectors, resulting in IPO levels similar...more

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 180: SCBIO and the Life Sciences Industry in South...

Maynard Nexsen on

Recorded at SCBIO’s 2024 annual conference, hosts Heather and Matthew welcome back James Chappell, the President and CEO of SCBIO. With a distinguished career in the biosciences industry, James is recognized for his...more

Latham & Watkins LLP

Life Sciences Product Development Needs More Creative Fundraising

Latham & Watkins LLP on

The life sciences industry depended historically on public offerings for fundraising to support costs of developing therapeutic pharmaceutical and biologic products. The average cost of discovering and developing these...more

Allen Matkins

Life Sciences Real Estate Update 10.16.23

Allen Matkins on

Boston, the San Francisco Bay Area, and San Diego are once again the top markets for life sciences commercial real estate in the U.S., with plenty of opportunities for growth as biotech readies for a comeback, according to a...more

Goodwin

New ISSB Sustainability Standards: A Long-awaited Milestone for Harmonising ESG-Related Disclosure

Goodwin on

On 26 June 2023, the International Sustainability Standards Board (“ISSB”) issued its first two sustainability standards, IFRS S1 and IFRS S2. These standards, which incorporate the recommendations of the Task Force on...more

Procopio, Cory, Hargreaves & Savitch LLP

Navigating a Tough Market: Insights and Strategies for Emerging Public Companies Raising Capital and Avoiding Delisting

After a market flush with cash and deal flow from 2020 through the first half of 2022, in the last six to twelve months the markets have been particularly tight. Particularly impacted in this turbulent market have been small...more

Fenwick & West LLP

Navigating Uncertain Times: IPO Insights for Late-Stage Technology and Life Sciences Companies - 2023

Fenwick & West LLP on

After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more

Wilson Sonsini Goodrich & Rosati

2021 Mid-Year Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2021 Mid-Year Technology and Life Sciences IPO Report presents analyses related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies...more

Goodwin

UK Listings Review: Do New Recommendations Change The Game For Tech And Life Sciences Companies?

Goodwin on

The review of the UK Listing Rules was launched by HM Treasury (the Treasury) late last year and has made a number of wide-ranging recommendations of relevance for our tech and life sciences clients who have ambitions to go...more

Wilson Sonsini Goodrich & Rosati

2020 Technology and Life Sciences IPO Report

Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1...more

Rothwell, Figg, Ernst & Manbeck, P.C.

The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics

The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma...more

Latham & Watkins LLP

PE Views: Insights on the World of Private Equity - December 2020

Latham & Watkins LLP on

Emerging companies have historically been backed by venture capital funds, but as Europe’s startup scene matures, involvement by more traditional private equity investors is growing, particularly in the tech, consumer, and...more

Fenwick & West LLP

Key Metrics for U.S. Technology and Life Sciences IPO Survey – 2020 First Half

Fenwick & West LLP on

Key Metrics for Recent Technology and Life Sciences Initial Public Offerings - Following a volatile spring 2020 due to the rapid global spread of the novel coronavirus, the capital markets, including IPOs, appear to be...more

Fenwick & West LLP

Key Metrics for Technology and Life Sciences Initial Public Offerings - 2019 Full Year

Fenwick & West LLP on

Survey Results - Life Sciences and Technology IPOs Stay Strong in Second Half Despite Bumps - U.S. initial public offerings notched another robust year in 2019 despite bouts of volatility, a number of high-profile...more

Wilson Sonsini Goodrich & Rosati

2019 Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2019 Technology and Life Sciences IPO Report presents analysis related to the closing of 87 initial public offerings completed by U.S.-based technology and life sciences issuers between...more

Mayer Brown Free Writings + Perspectives

Healthcare and Tech Remain Strong During Slow IPO Market

US IPO volume has declined by almost a quarter year-over-year, according to EY’s recent Global IPO trends report.  To date, $44.5 billion in proceeds have been raised in 127 IPOs, 23% less than at the end of Q3 2018. The...more

Arnall Golden Gregory LLP

[Webinar] Money, Money, Money: Raising Capital and Exit Transactions for Life Sciences Companies - October 3rd, 12:00 pm ET

Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more

Wilson Sonsini Goodrich & Rosati

2019 Mid-Year Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2019 Mid-Year Technology and Life Sciences IPO Report presents analysis related to the pricing of 49 initial public offerings completed by U.S.-based technology and life sciences issuers...more

McDermott Will & Emery

Proactive Due Diligence Considerations for Life Sciences Dealmakers

In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the...more

58 Results
 / 
View per page
Page: of 3

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide